Accelerate your cell and gene therapeutic pipeline with IDT Biologika's AAV & LVV platforms

At IDT Biologika, we are proud to unveil our innovative cell and gene therapy solutions for clinical and commercial manufacturing to establish both quality attributes and speed to market. Building upon our industry leading knowledge of virus and viral vectors, IDT Biologika’s next generation AAV and LVV platforms expand on the company’s success and partnerships with our clients. Our commitment over the last 100 years on the scientific advancement of vaccines and other biologics, drove us to explore additional solutions in advanced therapies. To achieve this, we set out by first heavily investing in our R&D groups both in Rockville and Dessau. Having produced one of the first commercial CGT products approved by the FDA and EMA, we strive to bring the next generation of therapeutics to market.

IDT Biologika’s AAV and LV platform processes are scalable, cGMP-ready and may accelerate the process development timeline. They are applicable for all standard AAV serotypes and LVV variants.

With sites both in Europe and the USA, IDT Biologika offers both the flexibility and redundant capabilities that reduce manufacturing complexities often found in the market. Our expertise and capabilities allowed us to produce our own HEK293 production cell lines utilizing a wide variety of upstream platforms including iCellis, Cell Stacks, Univercells, and Stir Tank Reactors. Along with our own AAV and LLV platforms, we offer the flexibility to take on your project as a tech transfer for clinical or commercial supply.

Our upstream and downstream suspension or adherent capabilities range from 50 L – 2,000 L, and up to 2 x 500 sqm, respectively and all Cell and Gene therapy specific Quality Control Testing can be done in-house.

Join our Live Event and learn more.

Ultimately, our goal is to transform lives. We have seen firsthand the life-changing impact of cell and gene therapies produced at our facilities on patients and their families. Our team works tirelessly to push the boundaries of what is possible and ensure we manufacture and deliver therapies with the best outcomes for patients. IDT Biologika’s highly experienced people and their commitment are only a part of our strengths that make our cell and gene therapy CDMO solutions unique.

View our online webinar and listen to experts from IDT Biologika to learn more about overcoming challenges in AAV and LV viral vector manufacturing.